Harnessing Host Defense Responses To Fight Cancer
Manhattan BioSolutions is an emerging biotech company focused on the development of novel biologic therapies that target microbial recognition and host-defense pathways for the treatment of advanced, metastatic cancers. We develop innovative tumor-targeted agents that selectively destroy cancer cells while sparing healthy tissues
Scientific Platforms
Degrader Nucleases
Developing a new generation of human nuclease therapeutics with potent anti-cancer activities. The RNA degrador platform utilizes engineered derivative of naturally occurring enzyme involved in host defense to selectively degrade RNA in tumors
ADCs & Ab Fusions
Developing novel biologics – ADCs & mAb-fusions that target cell-surface receptors overexpressed in tumors. The ADCs are designed to selectively eliminate cancer cells via multiple immune-mediated or direct anti-tumor mechanisms
In the News
